Atrial fibrillation (AF) is an increasingly widespread healthcare problem. AF can frequently present as a complication in acute coronary syndromes (ACS), especially in ST-elevation acute myocardial infarction (AMI), in which case it is the most frequent supraventricular rhythm disturbance with an estimated incidence of 6.8-21%. The presence of AF in ACS heralds worse outcomes in comparison to subjects in sinus rhythm, and several studies have shown that in AMI patients, both new-onset and pre-existing AF are associated with a higher risk of major adverse cardiovascular and cerebrovascular events during hospitalization. The cause of newonset AF in AMI is multifactorial. Although still incompletely understood, the mechanisms involved in the development of AF in acute myocardial ischemic events include the neurohormonal activation of the sympathetic nervous system that accompanies the AMI, ischemic involvement of the atrial myocytes, ventricular dysfunction, and atrial overload. The identification of patients at risk for AF is of great significance as it may lead to prompt therapeutic interventions and closer follow-up, thus improving prognosis and decreasing cardiovascular and cerebrovascular events. The present manuscript aims to summarize the current research findings related to new-onset AF in AMI patients, as well as the predictors and prognostic impact of this comorbid association.
tropic or vasoactive agents. Other reported risk factors for AF include diabetes, metabolic syndrome, chronic renal failure, or extensive myocardial ischemia, which encompasses a large portion of the left ventricle as well as the atrial myocytes. 8, 10, 11 The presence of AF in ACS heralds worse outcomes in comparison to subjects in sinus rhythm, since several studies have shown that both new-onset and pre-existing AF are significantly associated with the risk of major adverse cardiovascular and cerebrovascular events during hospitalization. 12, 13 In addition to the increased cardiovascular burden and impaired prognosis, the comorbid relation between AMI and AF also attracts higher healthcare costs. The estimated costs used in out-patient treatment, hospitalizations, and medical treatments for AF have been reported around 6.6 billion dollars annually, while the associated costs for a single acute coronary event have been estimated between 34,087-86,914 dollars in 2005, in the United States. The approximate costs increase by up to 40% if an ACS patient presents AF as a complication. [14] [15] [16] The present manuscript aims to summarize the current research findings related to new-onset AF in AMI patients, as well as the predictors and prognostic impact of this comorbid association.
ETIOLOgY AND CONSEquENCES Of Af IN AMI
The cause for new-onset AF in AMI subjects is multifactorial, various factors as well as a genetic dimension being reported. AF leads to the deterioration of coronary perfusion and ischemia, with a negative impact on patient outcomes. Although still incompletely understood, the mechanisms involved in the development of AF in acute myocardial ischemic events include the neurohormonal activation of the sympathetic nervous system that accompanies the AMI, ischemic involvement of the atrial myocytes, ventricular dysfunction, and atrial overload. 17, 18 In general, AF is triggered by focal automaticity and electrical re-entry in the area surrounding the pulmonary veins.
Several factors have been reported to be associated with AF in AMI patients, such as hypertension, metabolic disorders, structural or valvular heart disease. The arrhythmia itself leads to a structural remodeling of the atria with subsequent fibrosis, adipose infiltration, inflammatory infiltrates, which will ultimately lead to the so-called "electrical remodeling" that is optimal for developing reentrant circuits within the atrial wall and perpetuation of the arrhytmia. [19] [20] [21] The various physiopathological mechanisms in AF initiation and persistence include stretchinduced myocardial fibrosis, which may be caused by left ventricular overload, and dysfunction secondary to acute infarctions. In acute coronary events, AF can also result from a decreased contractility of the atrial myocardium, caused by involvement of the atrial branch of the coronary artery, by fatty infiltration or inflammation, or by calcium imbalance.
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AtriAl ischemiA
The ischemia of atrial myocytes as a trigger for new-onset AF has been suggested by a study that had experimentally induced atrial branch occlusions on animal models, leading to prolonged atrial conduction, increased electrical heterogeneity, and higher rates of induced atrial fibrillation episodes. These episodes had an increased likelihood to persist, compared to controls or to animals with left anterior descendant occlusions. 26 A study on 149 patients with ACS, out of which 4.9% had developed AF during hospitalization, showed that although there were no differences regarding the cardiovascular risk profile and associated disease, patients with atrial branch atherosclerosis or ischemic involvement of the atrial vasculature were more expected to present supraventricular arrhythmia. 27 These studies suggest that the arrhythmia is triggered by the compromised atrial coronary vasculature rather than neurohormonal activation.
AtriAl stretch And neurohormonAl ActivAtion
Increased stretch of the atrial wall is caused by various disorders that lead to increased volume overload either directly, as in atrioventricular valve regurgitation, or secondary to left ventricular increased pressures, in congestive heart failure, acute heart failure caused my myocardial ischemia, aortic valve disease, or structural cardiac diseases. The increased left ventricular pressure is transmitted to the left atrium, leading to neurohormonal activation, which has been implicated in fibrosis formation and cardiac remodeling via the renin-angiotensinaldosterone pathways. In addition, the increased left ventricular wall stress leads to overstimulation of the same neurohormonal system, consequent heart failure and atrial remodeling, both structurally and electrically.
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The acute myocardial ischemia, as well as the mitral regurgitation due to papillary ischemia, enhance the atrial overload and trigger AF with rapid ventricular response, which will, in turn, worsen the already altered coronary perfusion, decrease the cardiac output secondary to the loss of atrial contraction, and also impair the diastolic and systolic function of the left ventricle. The decreased cardiac output will further stimulate the sympathetic nervous system, with secondary adrenergic stimulation that leads to the creation of a vicious circle, with higher ventricular overload, more enhanced atrial stretch, and even more increased neurohormonal activation, ultimately leading to extension of the infarction and worse outcomes. [31] [32] [33] [34] inflAmmAtory response As A trigger for
Af in the post-infArction period
Several studies have linked an increased inflammatory response with the development and persistence of AF.
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The independent association between AF and the serum level of C-reactive protein (CRP), which is illustrative for an acute-phase inflammatory response, increases the likelihood of AMI patients to develop the supraventricular arrhytmia. 39, 40 Myocardial ischemia has been linked to increased inflammatory response. [41] [42] [43] [44] [45] [46] Acute myocardial ischemia leads to an intense inflammatory response which is of utmost importance for the process of cardiac repair. The exacerbation of this normal repair mechanism can lead to further promotion of myocardial damage and left ventricular remodeling, with subsequent development of heart failure following MI. [47] [48] [49] C-reactive protein as a marker for sustained inflammation following an acute MI can be induced by myocardial ischemia and existing unstable coronary plaques and has been established as a novel predictor for cardiovascular disease, as well as a predictor for adverse outcomes in MI. [50] [51] [52] [53] Other inflammatory biomarkers that present elevated serum levels following an AMI include tumor necrosis factor alpha, interleukin-6, or macrophage migration inhibitory factor, which have also been linked to mortality rates and adverse events following an acute coronary syndrome.
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Inflammation has also been incriminated in the development and persistence of AF. 57, 58 The first observation that led to the hypothesis that inflammation may have a role in the genesis of the supraventricular arrhythmia was its higher incidence in patients with clinical conditions that are associated with enhanced inflammatory response, such as pericarditis and myocarditis, or cardiac surgery.
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The contribution of the inflammatory process in AF has been proved by histological studies on atrial biopsies in patients with lone atrial fibrillation in which several inflammatory infiltrates were observed. 0.56 ± 0.24 mg/dL after, p = 0.42). 63 In a study that analyzed 971 patients with significant coronary artery disease, several inflammatory cytokines, such as interleukin-6, as well as an increased left atrial diameter have been shown to correlate with the genesis and duration of AF. 64 Elevated levels of TNF-alpha, interleukin-8, interleukin-10, and monocyte chemoattractant protein-1 (MCP-1) were found in a higher number of patients with persistent AF compared to paroxysmal AF and arrhythmic patients compared to sinus-rhythm controls. [65] [66] [67] The enhanced inflammatory response expressed either locally or at a systemic level, 68 seems to be also one of the factors intertwined in the thrombogenic milieu present in the atria of AF subjects, alongside endothelial dysfunction and platelet activation. 35, 59 A study has shown that increased serum interleukin-6 was an independent predictor for stroke and death in a follow-up period of 6 years, 69 while another research has linked high CRP values with the incidence of spontaneous echo contrast in the left atrial cavity and appendage. 70 This bidirectional relationship, inflammation -arrhythmia -inflammation, in the sense that AF is triggered but also generates an inflammatory response, could be one of the explanations of the "AF begets AF" concept. The study also showed that negative outcomes are persistently independent of the arrhythmia onset, while new-onset AF is significantly associated with higher death rates even after adjustments for age, diabetes, increased blood pressure, chronic congestive heart failure, previous myocardial infarction, or coronary revascularization, which have all been associated with increased mortality both in patients with AMI and chronic AF. parameters. The same study revealed that AF was more frequently associated with reinfarction, cerebrovascular accidents, congestive heart failure, and admissions in the Intensive Care Unit (ICU), while the overall hospitalization period was significantly longer in arrhythmic subjects compared to sinus rhythm controls (9.6 days vs. 7.6 days, p <0.0001).
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PREDICTORS fOR Af IN AMI
Given the associated risk of AF in AMI and its prognostic value in patients with ACS, it would be useful to identify patients at risk for the new onset of this supraventricular arrhythmia.
The 82 Other studies found that females were more prone to develop arrhythmia, and other baseline characteristics that were commonly found in patients with AF and AMI were diabetes, hypertension, increased left atrial diameter, lower left ventricular ejection fraction, and impaired renal function.
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The type of reperfusion treatment applied for the AMI (thrombolysis or percutaneous revascularization) was not
shown to significantly impact the risk of AF. 88 Furthermore, as shown by the RICO study on a cohort of 1,701 patients, there were no differences in the rate of new-onset AF in patients with ST-elevation and non-ST elevation AMI (7.6% vs. 7.7% respectively, p = 0.334). 89 Another study showed no significant difference in the rate of AF in 
